Healthcare / Drug Manufacturers - Specialty & GenericTokyo
$1679.00
-38.00 (-2.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF $3.0B · quality 60.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
31/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$32.0B
P/E
9.3x
↓EV/EBITDA
4.3x
↓ROE
18.3%
↑Gross Margin
69.4%
↑Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-13.8%
FCF CAGR
-34.6%
FCF margin
14.9%
FCF / Net income
0.49x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $11.26B · net income $3.42B · FCF $1.67B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $11.26B | $11.26B | $11.43B | $10.99B | $17.58B |
| Net Income | $3.42B | $3.42B | $3.77B | $3.77B | $7.84B |
| EBITDA | $4.92B | $4.92B | $5.15B | $5.35B | $11.29B |
| EPS | — | — | 198.12 | 198.13 | 411.47 |
| Gross Margin | 69.4% | 69.4% | 70.7% | 73.5% | 80.2% |
| Operating Margin | 41.3% | 41.3% | 43.1% | 46.9% | 63.2% |
| Net Margin | 30.4% | 30.4% | 33.0% | 34.3% | 44.6% |
| Balance Sheet | |||||
| Current Ratio | 11.59 | 11.59 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.67B | $1.67B | $3.05B | $3.72B | $5.99B |
| Returns | |||||
| ROE | 18.3% | 18.3% | 21.7% | 24.1% | 54.9% |
| Valuation | |||||
| P/E | 9.34 | 9.34 | 7.58 | 8.26 | 4.16 |
| EV/EBITDA | 4.30 | 4.30 | 3.37 | 3.94 | 2.12 |
| P/B | 1.71 | 1.71 | 1.65 | 1.99 | 2.28 |
| Growth & Yield | |||||
| Revenue Growth | -1.5% | -1.5% | 4.0% | -37.5% | — |
| EPS Growth | — | — | -0.0% | -51.8% | — |
| Dividend Yield | 5.9% | 5.9% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+19.5%
Start / end P/E
n/dx → n/dx
EPS bridge
198.12 → n/d
Residual
+13.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.